A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Trial Parameters
Brief Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Agree to follow the study treatment protocol and visit schedule, enroll voluntarily and sign a written informed consent; 2. Male or female aged ≥ 18 years at the time of signing the ICF; 3. B-cell lymphoma: ECOG performance status of 0-2; 4. Advanced solid tumors: ECOG performance status of 0-1; 5. Life expectancy of at least 3 months; 6. Dose escalation phase: Histopathologically confirmed relapsed/refractory B-cell lymphoma following at least 2 prior lines of systemic therapy; 7. Dose expansion phase: relapsed/refractory B-cell lymphoma and advanced or metastatic solid tumor of specified type. 8. All subjects are required to provide archived tissue (5 unstained sections) obtained within the previous 2 years or fresh tissue for ROR1 expression testing at the central laboratory; in addition, relapsed/refractory lymphoma subjects are required to provide tissue sections used for previous pathological diagnosis for pathological consultation at the central laboratory